HIV infection

12 trials 6 recruiting MedDRA PT
12 Registered trials
6 Recruiting
12 Unique sponsors
20 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
J Anti-infectives (ATC J) 4
B Haematology (ATC B) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
Antiviral 3 substances
NRTI 2 substances
Monoclonal antibody (immune) 1 substance
Vaccine 1 substance
HIV integrase inhibitor 1 substance
Supportive / diluent 1 substance
Monoclonal antibody 1 substance
Kinase inhibitor 1 substance
Phase III: 2 Phase II: 5 Phase I: 2 Phase I (Other): 2 Phase I (First in Human): 1

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

2 trials
  • Fondazione Penta Ets Academic
    ABACAVIR SULFATE; ABACAVIR SULFATE, LAMIVUDINE; ABACAVIR SULFATE, LAMIVUDINE, DOLUTEGRAVIR SODIUM; EMTRICITABINE, TENOFOVIR ALAFENAMIDE; EMTRICITABINE, TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE, DOLUTEGRAVIR SODIUM; ZIDOVUDINE; ZIDOVUDINE, LAMIVUDINE
    2024-520388-15-00 1 country 2023 n=6
    Ended
  • Inserm Academic
    DOLUTEGRAVIR SODIUM; EMTRICITABINE, TENOFOVIR DISOPROXIL; LAMIVUDINE, DORAVIRINE, TENOFOVIR DISOPROXIL
    2023-508626-10-00 1 country 2025 n=60
    Recruiting

Phase II

5 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BUDIGALIMAB; HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST ALFA4BETA7 INTEGRIN
    2023-505900-53-00 7 countries 2024 n=32
    Ended
  • Centre Hospitalier Universitaire De Bordeaux Academic
    RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
    2023-504482-23-00 1 country 2023 n=80
    Ended
  • Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal Academic
    DOLUTEGRAVIR SODIUM; LAMIVUDINE; MARAVIROC
    2024-513366-18-00 1 country 2025 n=24
    Recruiting
  • Imperial College London Limited Academic
    10-1074-LS; SODIUM CHLORIDE; TEROPAVIMAB
    2024-514564-13-00 6 countries 2025 n=21
    Recruiting
  • Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol Academic
    DASATINIB
    2024-513714-36-01 1 country 2024 n=60
    Ended

Phase I

2 trials
  • BioNTech SE Commercial
    IMP not specified
    2025-523846-29-00 1 country 2026 n=55
    Recruiting
  • Consorcio Centro De Investigacion Biomedica En Red Academic
    IMP not specified
    2025-520529-19-00 1 country 2026 n=12
    Ended

Phase I (Other)

2 trials
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2025-521102-17-00 1 country 2025 n=14
    Recruiting
  • Stichting Radboud University Medical Center Academic
    IMP not specified
    2023-510232-36-00 1 country 2024 n=20
    Ended

Phase I (First in Human)

1 trial
  • Immunocore Limited Commercial
    BISPECIFIC PROTEIN WITH A HIGH-AFFINITY T-CELL RECEPTOR DOMAIN FUSED TO AN ANTIBODY SINGLE-CHAIN VARIABLE FRAGMENT AGAINST CD3
    2024-513938-38-00 2 countries 2022 n=20
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BioNTech SE Commercial 1 Phase I 1
Merck Sharp & Dohme LLC Commercial 1 Phase I (Other) 1
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase II 0
Immunocore Limited Commercial 1 Phase I (First in Human) 1
Consorcio Centro De Investigacion Biomedica En Red Academic 1 Phase I 0
Stichting Radboud University Medical Center Academic 1 Phase I (Other) 0
Centre Hospitalier Universitaire De Bordeaux Academic 1 Phase II 0
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal Academic 1 Phase II 1
Imperial College London Limited Academic 1 Phase II 1
Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol Academic 1 Phase II 0
Fondazione Penta Ets Academic 1 Phase III 0
Inserm Academic 1 Phase III 1
New trials by year
2022
1
2023
2
2024
3
2025
4
2026
2
← All indication landscapes